Given that IL‐6 contributes to glioma immune escape [38], combinations that pair PD‐1/PD‐L1 inhibitors with IL‐6/STAT3 pathway modulators (or related JAK/STAT interventions) merit prospective testing to couple immune reinvigoration with inflammation dampening. This evidence concerns the gene CD274 and central nervous system cancer.